Pharma Journalist -

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million, for its NRF2 Activator programme.  AstraZeneca will develop…
Read More...

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted…
Read More...

SAE Media Group reports: Agenda and speaker overview released for the 6th Annual 3D Cell Culture Conference, London, UK SAE Media Group is delighted to announce the return of…
Read More...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a…
Read More...

The Global Antibiotic Research and Development Partnership (GARDP) and Mitsubishi Tanabe Pharma Corporation (MTPC) have signed an agreement for GARDP to access over 50,000 compounds…
Read More...

AbbVie announced the European Commission (EC) approved SKYRIZI (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) as the first specific…
Read More...

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…
Read More...

XtalPi announced that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their…
Read More...

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate…
Read More...

FUJIFILM Corporation announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will…
Read More...